<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754167</url>
  </required_header>
  <id_info>
    <org_study_id>PCS_02_15</org_study_id>
    <nct_id>NCT02754167</nct_id>
  </id_info>
  <brief_title>Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients</brief_title>
  <official_title>Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pieris Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pieris Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anticalins® are engineered human proteins that are able to bind specific target molecules.&#xD;
      The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin&#xD;
      and is intended for the treatment of anemia of chronic disease. This Phase Ib study shall&#xD;
      investigate the safety, pharmacokinetics and pharmacodynamics of a single administration of&#xD;
      PRS-080#022-DP in anemic stage 5 chronic kidney disease patients undergoing hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, single ascending dose&#xD;
      phase Ib study in anemic stage 5 chronic kidney disease patients requiring hemodialysis.&#xD;
      Eligible subjects will undergo screening assessments and PRS-080#22-DP will be administered&#xD;
      by intravenous infusion. The study will consist of 3 dose cohorts of 2 mg/kg, 4 mg/kg, and 8&#xD;
      mg/kg body weight with 8 subjects in each cohort. Using a standard 6+2 design, 6 subjects in&#xD;
      each cohort will be randomized to PRS-080#022-DP and 2 subjects in each cohort will be&#xD;
      randomized to placebo. The decision to escalate the dose will be based on an interim analysis&#xD;
      of clinical safety and safety laboratory data. Safety and tolerability, pharmacokinetics,&#xD;
      pharmacodynamics as well as potential immunogenicity will be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">June 6, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">February 6, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Composite measure including signs and symptoms, changes from baseline heart rate and blood pressure, ECG, body temperature, respiratory rate clinical chemistry and hematology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PRS-080#022</measure>
    <time_frame>28 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of PRS-080 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of PRS-080#022 on serum iron</measure>
    <time_frame>28 days</time_frame>
    <description>Changes in total serum iron concentration compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of PRS-080#022 on ferritin</measure>
    <time_frame>28 days</time_frame>
    <description>Changes in serum ferritin concentration compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of PRS-080#022 on transferrin saturation</measure>
    <time_frame>28 days</time_frame>
    <description>Changes in serum transferrin saturation compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of PRS-080#022 on hepcidin concentrations in plasma</measure>
    <time_frame>28 days</time_frame>
    <description>Changes in hepcidin concentration compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients developing anti-drug antibodies</measure>
    <time_frame>28 days</time_frame>
    <description>Number of patients with antibodies against PRS-080#022 at day 28 compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Anemia of Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>PRS-080#022-DP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepcidin antagonist, single administration, ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRS-080-Placebo#001</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comparator treatment, single administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRS-080#022-DP</intervention_name>
    <description>Hepcidin antagonism to mobilize iron and to treat anemia</description>
    <arm_group_label>PRS-080#022-DP</arm_group_label>
    <other_name>PRS-080</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRS-080-Placebo#001</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>PRS-080-Placebo#001</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with stage 5 chronic kidney disease having been on hemodialysis for at least&#xD;
             90 days&#xD;
&#xD;
          -  Patients being on stable erythropoiesis-stimulating agent (ESA) dose&#xD;
&#xD;
          -  Hemoglobin (Hb) 9 - 11 g/dL&#xD;
&#xD;
          -  Ferritin ≥ 300 ng/mL.&#xD;
&#xD;
          -  Transferrin saturation (TSAT) ≤ 30%&#xD;
&#xD;
          -  Hepcidin 5 - 50 nmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anemia due to causes other than chronic kidney disease, including hemoglobinopathies,&#xD;
             hemolytic anemias, myelodysplasia or malignancy&#xD;
&#xD;
          -  Blood transfusion within 2 months before administration of study medication.&#xD;
&#xD;
          -  Iron treatment from 1 week before study medication administration until 1 week after&#xD;
             study medication administration.&#xD;
&#xD;
          -  Previous enrollment in this study&#xD;
&#xD;
          -  Current or previous (within 60 days before study medication administration) treatment&#xD;
             with another investigational drug and/or medical device or participation in another&#xD;
             clinical study.&#xD;
&#xD;
          -  Pregnancy or breast-feeding women of child bearing age.&#xD;
&#xD;
          -  Known allergy to any component of the PRS-080#022-DP formulation&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen, anti-hepatitis C virus antibody, or human&#xD;
             immunodeficiency virus&#xD;
&#xD;
          -  Planned surgery during the study period&#xD;
&#xD;
          -  Unwilling or unable to comply with the protocol, in the judgment of the investigator&#xD;
&#xD;
          -  Unstable angina, myocardial infarction, percutaneous transluminal coronary&#xD;
             angioplasty/stents, apoplexy or coronary artery bypass grafting &lt;3 months prior&#xD;
             screening.&#xD;
&#xD;
          -  Congestive heart failure: New York Heart Association Class III or IV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lutz Renders, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University, Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technical University, Medical Department</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://pieris.com</url>
    <description>Pieris Pharmaceuticals</description>
  </link>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepcidin</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>iron</keyword>
  <keyword>anemia of chronic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

